Association of Antenatal Corticosteroids and Magnesium Sulfate Therapy With Neurodevelopmental Outcome in Extremely Preterm Children

Samuel J Gentle, Waldemar A Carlo, Sylvia Tan, Marissa Gargano, Namasivayam Ambalavanan, Sanjay Chawla, Edward F Bell, Carla M Bann, Susan R Hintz, Roy J Heyne, Alan Tita, Rosemary D Higgins, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network, Samuel J Gentle, Waldemar A Carlo, Sylvia Tan, Marissa Gargano, Namasivayam Ambalavanan, Sanjay Chawla, Edward F Bell, Carla M Bann, Susan R Hintz, Roy J Heyne, Alan Tita, Rosemary D Higgins, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network

Abstract

Objective: To test the primary hypothesis that extremely preterm children antenatally exposed to both magnesium sulfate and antenatal corticosteroids have a lower rate of severe neurodevelopmental impairment or death compared with those exposed to antenatal corticosteroids alone.

Methods: This was a prospective observational study of children born at 22 0/7-26 6/7 weeks of gestation from 2011 to 2014 at Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network hospitals (N=3,093). The primary outcome was severe neurodevelopmental impairment or death at 18-26 months of corrected age follow-up based on exposure to antenatal corticosteroids and magnesium sulfate or antenatal corticosteroids alone. Secondary outcomes included components of severe neurodevelopmental impairment by exposure group and comparisons of severe neurodevelopmental impairment or death between children exposed to both antenatal corticosteroids and magnesium sulfate with those exposed to magnesium sulfate alone or to neither antenatal corticosteroids nor magnesium sulfate. Logistic regression models adjusted for background characteristics.

Results: Children exposed to both antenatal corticosteroids and magnesium sulfate had a lower rate of severe neurodevelopmental impairment or death (813/2,239, 36.3%) compared with those exposed to antenatal corticosteroids alone (225/508, 44.3%; adjusted odds ratio [aOR] 0.73; 95% CI 0.58-0.91), magnesium sulfate alone (47/89, 53%; aOR 0.49; 95% CI 0.29-0.82), or neither therapy (121/251; 48.2%; aOR 0.66, 95% CI 0.49-0.89). Similarly, children exposed to both antenatal corticosteroids and magnesium sulfate had a lower rate of death compared with either or neither therapy, but the rate of severe neurodevelopmental impairment among survivors did not differ between exposure groups.

Conclusion: In children born between 22 0/7 and 26 6/7 weeks of gestation, exposure to both antenatal corticosteroids and magnesium sulfate was associated with lower rates of severe neurodevelopmental impairment or death and death compared with exposure to antenatal corticosteroids alone.

Clinical trial registration: ClinicalTrials.gov, NCT00063063.

Conflict of interest statement

Financial Disclosure

Waldemar Carlo disclosed that they are a consultant for Mednax, and they receive expenses reimbursed for travel to board meetings. Roy Heyne disclosed Catholic Health Professionals of Houston paid honorarium for an ethics talk that he gave to this nonprofit entity last year. He is nonpaid board member of nonprofit Catholic Physicians Guild of Dallas, nonpaid regional director of Catholic Medical Association, and a nonpaid board member and officer of Low Birth Weight Development Center in Dallas. The other authors did not report any potential conflicts of interest.

Each author has confirmed compliance with the journal’s requirements for authorship.

Source: PubMed

3
Iratkozz fel